FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:838-840 February 19, 2009 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Carnitine palmitoyltransferase II (CPT2) deficiency is a rare autosomal recessive disorder of mitochondrial fatty acid oxidation. The most common form of this disorder is characterized by muscle stiffness, myalgia, and exercise intolerance,^1,2 and current dietary approaches often do not prevent attacks of rhabdomyolysis. We found that bezafibrate, a commonly used hypolipidemic drug,³ restored the capacity for normal fatty acid oxidation in muscle cells from patients with a mild form of CPT2 deficiency by stimulating the expression of the mutated gene.⁴

We evaluated the efficacy of bezafibrate as a treatment for the mild form of CPT2 deficiency in . . . [Full Text of this Article]

This article has been cited by other articles:

• Haller, R. G., Vissing, J. (2009). Drilling for Energy in Mitochondrial Disease. Arch Neurol 66: 931-932 [Full Text]